Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
255
Views
1
CrossRef citations to date
0
Altmetric
Articles

Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma

Matthew Hoa Department of Internal Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0001-7937-1557View further author information
ORCID Icon,
Maria Moscvinb Amyloidosis program, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USAView further author information
,
Soon Khai Lowc Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USAView further author information
,
Benjamin Evansb Amyloidosis program, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USAView further author information
,
Sara Closed LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAView further author information
,
Robert Schlossmand LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAView further author information
,
Jacob Laubachd LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAView further author information
,
Claudia Paba Pradad LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAView further author information
,
Brett Glotzbeckere Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USAView further author information
,
Paul G. Richardsond LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAView further author information
&
Giada Bianchib Amyloidosis program, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Pages 2403-2412 | Received 02 Dec 2021, Accepted 22 May 2022, Published online: 14 Jun 2022

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.